Valneva SE (VALN) Liabilities from Discontinued Operations (2023)
Valneva SE (VALN) posted quarterly Liabilities from Discontinued Operations of 1619308.93 for Q2 2023.
Valneva SE (VALN) Liabilities from Discontinued Operations (2023) Analysis & Trends
Valneva SE (VALN) has reported Liabilities from Discontinued Operations for 1 consecutive years, with 1619308.93 the latest figure, recorded in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.62 Mn |
| Jun 30, 2023 | 1.62 Mn |